Abcam, ab320854, Anti-Fragilis antibody [RM1224] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Multiclonal IFITM3 antibody. Carrier free. Suitable for Flow Cyt (Intra), IHC-P, WB, IP, ICC/IF, IHC-Fr and reacts with Mouse, Human, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Multiclonal,
Clone number:RM1224,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human, Rat,
Applications:Flow Cyt (Intra), WB, IHC-Fr, ICC/IF, IHC-P, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Unsuitable for human ICC

Product details:
ab320854 is the carrier-free version of
ab320853
What are recombinant multiclonals?
Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including:
- The sensitivity of polyclonal antibodies by recognising multiple epitopes
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
View our range of
recombinant multiclonal antibodies
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein known as Fragilis also called Interferon-induced transmembrane protein 3 (IFITM3) plays a role in cellular defense mechanisms. Fragilis is approximately 15 kDa in mass. It is commonly expressed in cells of the immune system such as lymphocytes and can also be found in various tissues including the lungs spleen and thymus. This protein includes a chain of functional domains that interact with cellular membranes contributing to its protective roles on the cellular level.
Biological function summary
IFITM3 acts as an antiviral protein that disrupts the life cycle of viruses entering human cells. It is a part of a family of transmembrane proteins that block viral replication by inhibiting the fusion of viral membranes with endosomal membranes. The presence of Fragilis in respiratory epithelial cells is integral to the immune response against viral infections. The protein acts as a barrier to viruses like influenza providing an innate immune defense mechanism.
Pathways
The involvement of IFITM3 is central to the immune signaling pathways specifically the interferon signaling pathway. Upon viral infection interferons upregulate IFITM3 enhancing its antiviral activities. Other proteins like STAT1 and STAT2 mediate this regulation. Additionally IFITM3 aligns with the pathways regulating cell membrane integrity and remodeling highlighting its multi-functional role beyond just antiviral defense.
Research highlights the relevance of IFITM3 in conditions such as influenza and COVID-19. In both cases higher expression levels correlate with better prognosis. For instance variations in IFITM3 expression or genetic mutations can affect susceptibility to severe influenza. Connections with proteins such as MxA and other IFITM proteins can influence these disease processes. These connections make Fragilis a target of interest for understanding and potentially mitigating the severity of viral infections.